248 related articles for article (PubMed ID: 8104068)
1. Scanning electron microscopy of multidrug resistant cells in haematological and mammary malignancies.
Galimberti S; Bianchi F; Bernardini N; Mattii L; Dolfi A; Lupetti M; Petrini M
Cell Mol Biol (Noisy-le-grand); 1993 Jul; 39(5):543-51. PubMed ID: 8104068
[TBL] [Abstract][Full Text] [Related]
2. Cytogenetic and molecular characterization of tumors in nude mice derived from a multidrug-resistant human leukemia cell line.
Hill AB; Beck WT; Trent JM
Cancer Res; 1988 Jan; 48(2):393-8. PubMed ID: 2891436
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.
Beck WT; Cirtain MC; Danks MK; Felsted RL; Safa AR; Wolverton JS; Suttle DP; Trent JM
Cancer Res; 1987 Oct; 47(20):5455-60. PubMed ID: 2888532
[TBL] [Abstract][Full Text] [Related]
4. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines.
Ford JM; Bruggemann EP; Pastan I; Gottesman MM; Hait WN
Cancer Res; 1990 Mar; 50(6):1748-56. PubMed ID: 1968358
[TBL] [Abstract][Full Text] [Related]
5. In vitro multidrug resistance of P388 murine leukemia selected for resistance to diaziquone.
Gutierrez PL; Wilder PJ; Biswal N
Cancer Commun; 1989; 1(3):181-90. PubMed ID: 2576972
[TBL] [Abstract][Full Text] [Related]
6. Pentose phosphate pathway alterations in multi-drug resistant leukemic T-cells: 31P NMR and enzymatic studies.
Ferretti A; Chen LL; Di Vito M; Barca S; Tombesi M; Cianfriglia M; Bozzi A; Strom R; Podo F
Anticancer Res; 1993; 13(4):867-72. PubMed ID: 8102518
[TBL] [Abstract][Full Text] [Related]
7. Medroxyprogesterone-acetate reverses the MDR phenotype of the CG5-doxorubicin resistant human breast cancer cell line.
Zibera C; Gibelli N; Maestri L; Della Cuna GR
Anticancer Res; 1995; 15(3):745-9. PubMed ID: 7645952
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of flow cytometry for multidrug resistance detection in low resistance K562 cells using daunorubicin and monoclonal antibodies.
Van Acker KL; Van Hove LM; Boogaerts MA
Cytometry; 1993 Oct; 14(7):736-46. PubMed ID: 7902231
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists.
Yang JM; Goldenberg S; Gottesman MM; Hait WN
Cancer Res; 1994 Feb; 54(3):730-7. PubMed ID: 7905786
[TBL] [Abstract][Full Text] [Related]
10. Establishment and serial quantification of intrahepatic xenografts of human hepatocellular carcinoma in severe combined immunodeficiency mice, and development of therapeutic strategies to overcome multidrug resistance.
Leveille-Webster CR; Arias IA
Clin Cancer Res; 1996 Apr; 2(4):695-706. PubMed ID: 9816220
[TBL] [Abstract][Full Text] [Related]
11. Characterization of monoclonal antibodies recognizing a Mr 180,000 P-glycoprotein: differential expression of the Mr 180,000 and Mr 170,000 P-glycoproteins in multidrug-resistant human tumor cells.
Meyers MB; Rittmann-Grauer L; O'Brien JP; Safa AR
Cancer Res; 1989 Jun; 49(12):3209-14. PubMed ID: 2566379
[TBL] [Abstract][Full Text] [Related]
12. Multidrug resistance of murine leukemia cells characterization and correlation with cytochrome P-450 dependent activities, cytosolic calcium and cell cycle state.
Pfeil D; Bergmann J; Fichtner I; Stein U; Hentschel M; Rothe I; Goan SR
Anticancer Res; 1994; 14(2A):571-6. PubMed ID: 7912495
[TBL] [Abstract][Full Text] [Related]
13. Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution.
Baldini N; Scotlandi K; Serra M; Shikita T; Zini N; Ognibene A; Santi S; Ferracini R; Maraldi NM
Eur J Cell Biol; 1995 Nov; 68(3):226-39. PubMed ID: 8603675
[TBL] [Abstract][Full Text] [Related]
14. Identification of a P-glycoprotein-related protein (mini-P-glycoprotein) which is overexpressed in multidrug resistant cells.
Kawai K; Kusano I; Ido M; Sakurai M; Shiraishi T; Yatani R
Biochem Biophys Res Commun; 1994 Jan; 198(2):804-10. PubMed ID: 7905266
[TBL] [Abstract][Full Text] [Related]
15. Establishment and characterization of multidrug-resistant human osteosarcoma cell lines.
Serra M; Scotlandi K; Manara MC; Maurici D; Lollini PL; De Giovanni C; Toffoli G; Baldini N
Anticancer Res; 1993; 13(2):323-9. PubMed ID: 8100126
[TBL] [Abstract][Full Text] [Related]
16. Improved flow-cytometric detection of low P-glycoprotein expression in leukaemic blasts by histogram subtraction analysis.
Müller MR; Lennartz K; Nowrousian MR; Dux R; Tsuruo T; Rajewsky MF; Seeber S
Cytometry; 1994 Jan; 15(1):64-72. PubMed ID: 7512893
[TBL] [Abstract][Full Text] [Related]
17. Detection of soluble P-glycoprotein in culture media and extracellular fluids.
Chu TM; Lin TH; Kawinski E
Biochem Biophys Res Commun; 1994 Aug; 203(1):506-12. PubMed ID: 7915520
[TBL] [Abstract][Full Text] [Related]
18. Biological effects of PEMF (pulsing electromagnetic field): an attempt to modify cell resistance to anticancer agents.
Pasquinelli P; Petrini M; Mattii L; Galimberti S; Saviozzi M; Malvaldi G
J Environ Pathol Toxicol Oncol; 1993; 12(4):193-7. PubMed ID: 8189374
[TBL] [Abstract][Full Text] [Related]
19. Ultrastructural changes related to multidrug resistance in CEM cells: role of cytoplasmic vesicles in drug exclusion.
Bobichon H; Colin M; Depierreux C; Liautaud-Roger F; Jardillier JC
J Exp Ther Oncol; 1996 Jan; 1(1):49-61. PubMed ID: 9414388
[TBL] [Abstract][Full Text] [Related]
20. Mr 85,000 membrane protein specifically expressed in adriamycin-resistant human tumor cells.
Hamada H; Okochi E; Watanabe M; Oh-hara T; Sugimoto Y; Kawabata H; Tsuruo T
Cancer Res; 1988 Dec; 48(24 Pt 1):7082-7. PubMed ID: 2903793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
